Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4

被引:238
作者
Cummins, CL [1 ]
Jacobsen, W [1 ]
Benet, LZ [1 ]
机构
[1] Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA
关键词
D O I
10.1124/jpet.300.3.1036
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drug efflux by intestinal P-glycoprotein (P-gp) is known to decrease the oral bioavailability of many CYP3A4 substrates. We hypothesized that the interplay occurring between P-gp and CYP3A4 at the apical membrane would increase the opportunity for drug metabolism. To define the roles of P-glycoprotein (P-gp) and CYP3A4 in controlling the extent of intestinal absorption and metabolism, two substrates were tested. The transport, metabolism, and intracellular levels of N-methyl piperazine-Phe-homoPhe-vinylsulfone phenyl (K77, a cysteine protease inhibitor; P-gp and. CYP3A4 substrate) and felodipine (CYP3A4 substrate only) were measured across CYP3A4-transfected Caco-2 cells in the presence of an inhibitor of CYP3A4 and P-gp, cyclosporine (CsA), or an inhibitor of P-gp and not CYP3A4, GG918(N-{4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)-ethyl]-phenyl}-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamine). The extent of metabolism was measured by calculating the extraction ratio (ER) across the cells, while accounting for intracellular changes occurring with P-gp inhibition. The (A)pical to (B)asolateral and B-->A ERs for K77 were 0.33 and 0.06, respectively. These changed with GG918 to 0.14 and 0.12 and with CsA to 0.06 and 0.04. Felodipine ERs were similar in both directions, 0.26. and 0.24 (A-->B and B-->A), and were unchanged in the presence of GG918 but decreased with CsA (0.14 and 0.11). The K77 absorption rate was increased 5 and 4.2-fold in the presence of CsA and GG918, respectively, whereas no change was observed for felodipine absorption. The decreased A-->B ER and increased absorption of K77 with GG918 suggest that P-gp influences the extent of drug metabolism In the intestine via prolonging the access of drugs to CYP3A4 near the apical membrane and decreasing transport across the cells.
引用
收藏
页码:1036 / 1045
页数:10
相关论文
共 40 条
  • [1] Biochemical, cellular, and pharmacological aspects of the multidrug transporter
    Ambudkar, SV
    Dey, S
    Hrycyna, CA
    Ramachandra, M
    Pastan, I
    Gottesman, MM
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1999, 39 : 361 - 398
  • [2] Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery
    Benet, LZ
    Wu, CY
    Hebert, MF
    Wacher, VJ
    [J]. JOURNAL OF CONTROLLED RELEASE, 1996, 39 (2-3) : 139 - 143
  • [3] Development of Caco-2 cells expressing high levels of cDNA-derived cytochrome P4503A4
    Crespi, CL
    Penman, BW
    Hu, M
    [J]. PHARMACEUTICAL RESEARCH, 1996, 13 (11) : 1635 - 1641
  • [4] Characterizing the expression of CYP3A4 and efflux transporters (P-gp, MRP1, and MRP2) in CYP3A4-transfected Caco-2 cells after induction with sodium butyrate and the phorbol ester 12-O-tetradecanoylphorbol-13-acetate
    Cummins, CL
    Mangravite, LM
    Benet, LZ
    [J]. PHARMACEUTICAL RESEARCH, 2001, 18 (08) : 1102 - 1109
  • [5] EDGAR B, 1992, EUR J CLIN PHARMACOL, V42, P313
  • [6] Fisher JM, 1999, J PHARMACOL EXP THER, V289, P1134
  • [7] Gan LSL, 1996, DRUG METAB DISPOS, V24, P344
  • [8] The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
    Greiner, B
    Eichelbaum, M
    Fritz, P
    Kreichgauer, HP
    Von Richter, O
    Zundler, J
    Kroemer, HK
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) : 147 - 153
  • [9] Hall Stephen D., 1999, Drug Metabolism and Disposition, V27, P161
  • [10] Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation
    Hashida, T
    Masuda, S
    Uemoto, S
    Saito, H
    Tanaka, K
    Inui, K
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (05) : 308 - 316